| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | n/a |
| Number of Subjects | 27 |
| Sex | n/a |
A dose of 135mg EGCG, after 45 minutes, resulted in less cerebral blood flow measured in the frontal cortex. A dose of 270mg did not have this effect.
Capsules had 94% EGCG by weight, 6% excipients. Caffeine content not stated but most likely inconsequential due to low dose.
No adverse effects were seen on cognition or mood.
